表紙
市場調査レポート

コンパニオン診断市場

Companion Diagnostics Markets (Cancer, Cardiovascular and Blood, Metabolic, Infection, Neurological and Others)

発行 Kalorama Information 商品コード 311712
出版日 ページ情報 英文 298 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
コンパニオン診断市場 Companion Diagnostics Markets (Cancer, Cardiovascular and Blood, Metabolic, Infection, Neurological and Others)
出版日: 2014年08月08日 ページ情報: 英文 298 Pages
概要

コンパニオン診断の市場が世界的に拡大するなか、多くの医薬品開発企業がこの分野での開発に力を注ぐようになっています。近年、がん治療の分野を中心に、多くのコンパニオン診断薬が市場に投入されており、通常の診断・治療計画に組み込まれているものもあります。これまで、コンパニオン診断のための検査薬は、米食品医薬品局(FDA)の承認を受けていないものが多かったため、製薬会社も普及拡大に向けて積極的に動くことができず、市場への浸透は進んでいませんでした。しかし、特定の疾病に対応する治療薬の恩恵が大きい患者を特定し、効果が期待できない患者を除外することにより、医療費の削減に貢献できるという認識が共有されるようになったことで、医療現場におけるコンパニオン診断の重要性は高まっており、米国や欧州の企業を中心に、市場参入の動きが活発化しつつあります。

当レポートは、世界のコンパニオン診断市場における新たな動きを追跡するとともに、2013年から2014年にかけて市場に投入された製品にスポットライトを当てたもので、がん、循環器と血液の疾患、代謝疾患、感染症、中枢神経系疾患の5分野における製品の分析と2018年までの予測に加え、主要企業のプロファイルも網羅します。

第1章 エグゼクティブサマリー

  • 概要
  • 調査範囲と手法
  • 全体の市場規模と成長性
  • 市場に影響を及ぼしている問題とトレンド
  • 競合関係にある主な企業

第2章 コンパニオン診断業界のイントロダクション

  • 概要
  • バイオマーカー
  • バイオマーカーのタイプ
  • 治療法選択ツールとしてのバイオマーカー
  • 治療監視ツールとしてのバイオマーカー
  • 個別化医療
  • 潜在的な利点
  • プライバシーと社会の認識

第3章 業界のトレンド

  • 保健業界
  • 人口動態
  • 平均余命
  • 慢性疾患の影響
  • 疾病と高齢化
  • 米国での医療改革
  • 共同開発と提携契約
  • コンパニオン診断のビジネスモデル
  • 償還の問題
  • 抗菌薬耐性
  • BRIC諸国の関与
  • 規制の構造
  • 分子検査費用の償還

第4章 コンパニオン診断製品

  • がん
  • 循環器疾患
  • 内分泌疾患、自己免疫疾患
  • 感染症
  • 中枢神経系疾患

第5章 市場規模と成長性

  • 市場の課題
  • 市場の概要
  • 各地域の市場

第6章 主要企業のプロファイル

  • イントロダクション
  • 20/20 GeneSystems, Inc.
  • Abbott Laboratories
  • Affymetrix
  • Agendia, Inc. USA
  • Alere, Inc
  • Asuragen, Inc.
  • Beckman Coulter, Inc
  • Becton, Dickinson
  • Biocartis S.A.
  • Biodesix, Inc.
  • bioMerieux SA
  • BioReference Laboratories, Inc
  • bioTheranostics, Inc.
  • CARDIODX, INC
  • CELERA ALAMEDA
  • Clarient, Inc
  • deCODE Genetics, Inc.
  • DiaGenic ASA
  • Genomic Health, Inc.
  • Genoptix Medical Laboratory
  • Illumina, Inc.
  • Johnson & Johnson
  • Life Technologies Corporation (Thermo Fisher傘下)
  • Memory Dx
  • Myriad Genetics, Inc.
  • Nanostring Technologies, Inc.
  • OPKO Health, Inc.
  • Provista Dx
  • Qiagen N.V.
  • Roche
  • SIEMENS HEALTHCARE
  • Singulex, Inc
  • Thermo Fisher Scientific

付録

目次
Product Code: KLI5310061

The global companion diagnostic market is on the rise, and companion diagnostic development is becoming a primary area of focus for pharmaceutical developers. Many companion diagnostics are now successfully marketed, mainly in the cancer segment, with several of them part of a routine diagnostic and treatment plan.

This report tracks these developments and provides detailed examples of drug-test pairs. It also provides market estimation and forecast models for business planning.

There had been a slow market uptake of companion diagnostics because companion tests lacked FDA approval, which prevented pharmaceutical companies from promoting the diagnostic. But the realization that companion diagnostics can decrease costs by identifying the patient population that will most likely benefit from a therapy and ruling out those therapies not likely to be effective has made companion diagnostics important to the delivery of care.

This report, Companion Diagnostics Markets tracks these new developments and focuses on companion diagnostics in medicine in 2013 and 2014. The report provides product analysis for the five broad areas of medical companion diagnostics and market information:

  • Cancer
  • Cardiovascular and Blood
  • Metabolic
  • Infection
  • Neurological
  • Market Size by Disease Area, 2013 and 2018

Companion diagnostics have met with considerable challenges in penetrating the market, but are now rising to the forefront of pharmaceutical development and treatment, increasing the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. Companion diagnostics and biomarkers provide insight into understanding disease processes and ways that medicines can work to counteract the disease.

The majority of competitive participation for companion diagnostics is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market which include large multiproduct companies such as Roche and Abbott and small niche developers such as 20/20 GeneSystems.

Companies profiles in this report include:

  • 20/20 GeneSystems
  • Abbott Laboratories
  • Affymetrix
  • Agendia
  • Alere
  • Beckman Coulter
  • Becton Dickinson
  • Biocartis SA
  • Biodesix
  • bioMerieux
  • BioReference Laboratory
  • bioTheranostics
  • CardioDX
  • Celera Alameda
  • Clarient
  • deCODE Genetics
  • DiaGenic
  • Genomic Health
  • Genoptix Medical Laboratory
  • Illumina
  • Johnson & Johnson
  • Life Techologies
  • Memory Dx
  • Myriad Genetics
  • Nanostring Technologies
  • OPKO Health
  • Provista Dx
  • Qiagen
  • Roche
  • Seimens Healthcare
  • Singulex
  • Thermo Fisher Scientific

The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers.

All market data are based on factory sales to the end user and not retail pricing or reimbursement payments. Market data pertains to the world market at the manufacturers' level. The base year for data was 2013. Historical data was provided for the years 2011 through 2013, with forecast data provided for 2014 through 2018. Compound annual growth rates (CAGRs) are provided for the 2011-2013 and 2013-2018 periods for each segment covered. Basic competitor summaries are included in each segment. The forecasted market analysis for 2013-2018 was largely based on demographic trends, new developments, biomarker development, companion diagnostic deals, company performance trends, merger and acquisitions, and global expansion.

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Overview
  • Scope and Methodology
  • Total Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

TWO: INTRODUCTION TO THE COMPANION DIAGNOSTICS INDUSTRY

  • Overview
  • Biomarkers
  • Types of Biomarkers
  • Biomarkers as Treatment Selection Tool
  • Biomarkers as Therapy Monitoring Tool
  • Personalized Medicine
  • Potential Benefits
  • Privacy and Public Perception

THREE: INDUSTRY TRENDS

  • The Health Industry
  • Population Demographics
  • Life Expectancy
  • Chronic Disease Impact
  • Disease and An Aging Population
  • Healthcare Reform in the United States
  • Co-Development and Partnership Deals
  • Companion Diagnostic Business Model
  • Reimbursement Issues
  • Antimicrobial Drug Resistance
  • BRIC Involvement
  • Regulatory Structure
  • Molecular Test Reimbursement

FOUR: COMPANION DIAGNOSTIC PRODUCTS

  • Cancer
  • Overview
  • Biochemistry of Cancer Cells
  • Carcinogen Metabolism
  • Causes of Cancer Growth
  • Environmental Factors, DNA, RNA
  • Cellular Oncogenes
  • Tumor Suppressor Genes
  • History of Cancer
  • Cancer Types
  • Cancer Biomarker Examples
  • New Developments
  • Cancer Companion Diagnostics
  • Selected Cancer Companion Diagnostics in Development
  • Cardiovascular
  • Overview
  • The Cardiovascular System
  • Heart
  • Circulatory System
  • Cardiac Cycle
  • Coronary Circulation
  • Cardiac Myocytes
  • Molecular Contraction
  • Cardiovascular and Blood Diseases
  • Ischemic Heart Disease
  • Chronic Ischemic Cardiomyopathy
  • Sudden Cardiac Death
  • Valvular and Endocardial Diseases
  • Mitral Valve Disorders
  • Aortic Valve Disorders
  • Rheumatic Heart Disease
  • Endocarditis
  • Pericardial Diseases
  • Pericardial Effusion
  • Pericarditis
  • Myocardial Diseases
  • Myocarditis
  • Cardiomyopathy
  • Congenital Heart Diseases
  • Atrial Septal Defect
  • Ventral Septal Defect
  • Pulmonary Stenosis
  • Aortic Stenosis
  • Coarctation of the Aorta
  • Patent Ductus Arteriosus
  • Truncus Arteriosus
  • Transposition of the Great Arteries
  • Tricuspid Atresia
  • Congestive Heart Failure
  • Etiology
  • Cardiac Dysrhythmias
  • Hypertension
  • Risk Factors
  • Effects of High Blood Pressure
  • Blood Disorders
  • Hyperlipidemia
  • Biomarker Availability
  • New Developments
  • Companion Diagnostics
  • Selected Cardiovascular Companion Diagnostics in Development
  • Endocrine, Autoimmune
  • Overview
  • The Endocrine System
  • Hormone Function
  • Hormone Synthesis
  • Immune System
  • Autoimmunity
  • Genetic Factors
  • Environmental Factors
  • Inflammatory Disorders
  • Disease Overview
  • Classification of Endocrine Disorders
  • Growth Hormone Disorders
  • 1Etiology of Growth Hormone
  • Antidiuretic Hormone Disorders
  • Etiology
  • Thyroid Hormone Disorders
  • Hypothyroidism
  • Hyperthyroidism
  • Adrenocortical Hormone Disorders
  • Diabetes Mellitus
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Rheumatic Arthritis
  • Biomarker Availability
  • New Developments
  • Companion Diagnostics
  • Infectious Disease
  • Overview
  • Infection
  • Infectious Diseases
  • HIV Disease
  • Hepatitis C
  • Human Papillomavirus (HPV)
  • Sepsis
  • Biomarker Availability
  • New Developments
  • Companion Diagnostics
  • Central Nervous System
  • Overview
  • The Nervous System
  • Central Nervous System
  • Peripheral Nervous System
  • Autonomic Nervous System
  • Nervous System Disorders
  • Alzheimer's Disease
  • Multiple Sclerosis
  • Parkinson's Disease
  • Stroke
  • Biomarker Examples
  • New Developments
  • Companion Diagnostics

FIVE: MARKET SIZE AND GROWTH

  • Market Considerations
  • Market Overview
  • Companion Diagnostics Market by Geographical Region

SIX: COMPANY PROFILES

  • Introduction
  • 20/20 GeneSystems, Inc.
  • Company Overview
  • Abbott Laboratories
  • Company Overview
  • Affymetrix
  • Company Overview
  • Agendia, Inc. USA
  • Company Overview
  • Alere, Inc
  • Company Overview
  • Asuragen, Inc.
  • Company Overview
  • Beckman Coulter, Inc
  • Company Overview
  • Becton, Dickinson
  • Company Overview
  • Biocartis S.A.
  • Company Overview
  • Biodesix, Inc.
  • Company Overview
  • bioMerieux SA
  • Company Overview
  • BioReference Laboratories, Inc
  • Company Overview
  • bioTheranostics, Inc.
  • Company Overview
  • CARDIODX, INC
  • Company Overview
  • CELERA ALAMEDA
  • Company Overview
  • Clarient, Inc
  • Company Overview
  • deCODE Genetics, Inc.
  • Company Overview
  • DiaGenic ASA
  • Company Overview
  • Genomic Health, Inc.
  • Company Overview
  • Genoptix Medical Laboratory
  • Company Overview
  • Illumina, Inc.
  • Company Overview
  • Johnson & Johnson
  • Company Overview
  • Life Technologies Corporation (part of Thermo Fisher)
  • Company Overview
  • Memory Dx
  • Company Overview
  • Myriad Genetics, Inc.
  • Company Overview
  • Nanostring Technologies, Inc.
  • Company Overview
  • OPKO Health, Inc.
  • Company Overview
  • Provista Dx
  • Company Overview
  • Qiagen N.V.
  • Company Overview
  • Roche
  • Company Overview
  • SIEMENS HEALTHCARE
  • Company Overview
  • Singulex, Inc
  • Company Overview
  • Thermo Fisher Scientific
  • Company Overview

APPENDIX: LIST OF CONTRIBUTORS

Back to Top